Allianz Asset Management GmbH Sells 79,318 Shares of Charles River Laboratories International, Inc. (CRL)

Allianz Asset Management GmbH decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 29.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,099 shares of the medical research company’s stock after selling 79,318 shares during the quarter. Allianz Asset Management GmbH owned 0.40% of Charles River Laboratories International worth $20,318,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC lifted its position in Charles River Laboratories International by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after buying an additional 891 shares during the last quarter. Advisor Group Inc. lifted its position in Charles River Laboratories International by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after buying an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after buying an additional 247 shares during the last quarter. Finally, Advisor Partners LLC bought a new stake in Charles River Laboratories International in the 2nd quarter worth approximately $208,000. Institutional investors own 96.27% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE CRL) opened at $103.90 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories International, Inc. has a 12 month low of $73.13 and a 12 month high of $119.05. The company has a market capitalization of $4,918.02, a P/E ratio of 20.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the firm earned $1.18 earnings per share. The business’s revenue was up 9.0% compared to the same quarter last year. equities analysts predict that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current fiscal year.

In other news, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total transaction of $678,150.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Over the last three months, insiders have bought 10,500 shares of company stock worth $2,885 and have sold 1,016,392 shares worth $1,995,395. 2.20% of the stock is currently owned by insiders.

A number of analysts recently weighed in on CRL shares. Robert W. Baird restated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Bank of America decreased their price target on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Tuesday, October 24th. Royal Bank of Canada started coverage on Charles River Laboratories International in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price target on the stock. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $106.63.

COPYRIGHT VIOLATION NOTICE: “Allianz Asset Management GmbH Sells 79,318 Shares of Charles River Laboratories International, Inc. (CRL)” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/12/allianz-asset-management-gmbh-sells-79318-shares-of-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply